|
EA037918B1
(ru)
|
2011-12-21 |
2021-06-07 |
Новира Терапьютикс, Инк. |
Противовирусные агенты против гепатита в
|
|
HK1208465A1
(en)
|
2012-08-28 |
2016-03-04 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
DK2961732T3
(en)
|
2013-02-28 |
2017-07-10 |
Janssen Sciences Ireland Uc |
SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
|
|
WO2014161888A1
(en)
|
2013-04-03 |
2014-10-09 |
Janssen R&D Ireland |
N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
RS57999B1
(sr)
|
2013-05-17 |
2019-01-31 |
Janssen Sciences Ireland Uc |
Derivati sulfamoiltiofenamida i njihova primena kao lekovi za tretman hepatitisa b
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
ES2774749T3
(es)
|
2013-07-25 |
2020-07-22 |
Janssen Sciences Ireland Unlimited Co |
Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
|
|
KR102290189B1
(ko)
|
2013-10-23 |
2021-08-17 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
KR20160128305A
(ko)
|
2014-02-05 |
2016-11-07 |
노비라 테라퓨틱스, 인코포레이티드 |
Hbv 감염의 치료를 위한 병용 요법
|
|
DK3102572T3
(en)
|
2014-02-06 |
2019-02-04 |
Janssen Sciences Ireland Uc |
SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
|
|
CN112375078B
(zh)
|
2014-12-18 |
2023-12-19 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
|
WO2016146591A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Astrazeneca Ab |
Combination treatment
|
|
WO2016149581A1
(en)
|
2015-03-19 |
2016-09-22 |
Novira Therapeutics, Inc. |
Azocane and azonane derivatives and methods of treating hepatitis b infections
|
|
MX372914B
(es)
|
2015-06-16 |
2020-04-27 |
Jiangsu Hengrui Medicine Co |
Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
HK1259410A1
(zh)
|
2015-09-29 |
2019-11-29 |
诺维拉治疗公司 |
乙型肝炎抗病毒剂的晶体形式
|
|
KR102710603B1
(ko)
*
|
2015-10-01 |
2024-09-27 |
올레마 파마슈티컬스 인코포레이티드 |
테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
|
|
US10519148B2
(en)
|
2015-11-12 |
2019-12-31 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Acrylic acid derivative, preparation method and use in medicine thereof
|
|
NZ743651A
(en)
|
2015-12-09 |
2023-07-28 |
Univ Illinois |
Benzothiophene-based selective estrogen receptor downregulators
|
|
BR112018011817A2
(pt)
|
2015-12-22 |
2018-12-04 |
Jiangsu Hengrui Medicine Co |
derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo
|
|
WO2017136688A1
(en)
*
|
2016-02-05 |
2017-08-10 |
Inventisbio Inc. |
Selective estrogen receptor degraders and uses thereof
|
|
CA3017388C
(en)
*
|
2016-04-01 |
2024-03-12 |
Zeno Royalties & Milestones, LLC |
Estrogen receptor modulators
|
|
EP3442524A2
(en)
|
2016-04-15 |
2019-02-20 |
Novira Therapeutics Inc. |
Combinations and methods comprising a capsid assembly inhibitor
|
|
US10125135B2
(en)
|
2016-04-20 |
2018-11-13 |
Astrazeneca Ab |
Chemical compounds
|
|
JP7131773B2
(ja)
*
|
2016-04-29 |
2022-09-06 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ホルモン受容体に関連する転写活性の標的尺度
|
|
WO2017197904A2
(zh)
*
|
2016-05-08 |
2017-11-23 |
上海诚妙医药科技有限公司 |
帕布昔利布的新晶型及其制备方法及其用途
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
ES2989988T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros heterorocíclicos para la degradación de proteínas diana
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
WO2017197051A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Amine-linked c3-glutarimide degronimers for target protein degradation
|
|
CN109311876B
(zh)
*
|
2016-06-16 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
杂芳基雌激素受体调节剂及其用途
|
|
WO2017216280A1
(en)
|
2016-06-16 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
|
WO2018001232A1
(zh)
*
|
2016-06-29 |
2018-01-04 |
浙江海正药业股份有限公司 |
丙烯酸类衍生物及其制备方法和其在医药上的用途
|
|
EA201990187A1
(ru)
|
2016-07-01 |
2019-07-31 |
Г1 Терапьютикс, Инк. |
Антипролиферационные средства на основе пиримидина
|
|
US10149839B2
(en)
|
2016-07-25 |
2018-12-11 |
Astrazeneca Ab |
Chemical compounds
|
|
CN107814798B
(zh)
*
|
2016-09-14 |
2020-11-03 |
四川科伦博泰生物医药股份有限公司 |
3-取代丙烯酸类化合物及其制备方法和用途
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
LT3640251T
(lt)
|
2016-10-24 |
2022-03-10 |
Astrazeneca Ab |
6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
TWI823845B
(zh)
|
2017-01-06 |
2023-12-01 |
美商G1治療公司 |
用於治療癌症的組合療法
|
|
WO2018130124A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的三环类化合物及其应用
|
|
WO2018130123A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的五环类化合物及其应用
|
|
MX2019008438A
(es)
*
|
2017-01-30 |
2019-10-30 |
Astrazeneca Ab |
Moduladores del receptor de estrogeno.
|
|
EP3580212A4
(en)
|
2017-02-08 |
2021-03-17 |
Dana Farber Cancer Institute, Inc. |
REGULATION OF CHEMERIC ANTIGEN RECEPTORS
|
|
WO2018148576A1
(en)
|
2017-02-10 |
2018-08-16 |
G1 Therapeutics, Inc. |
Benzothiophene estrogen receptor modulators
|
|
CN108864080B
(zh)
*
|
2017-05-09 |
2021-10-15 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的四环类化合物及其应用
|
|
CN110536888B
(zh)
*
|
2017-06-20 |
2022-07-26 |
江苏恒瑞医药股份有限公司 |
一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
EP4455146A3
(en)
|
2017-06-29 |
2025-01-01 |
G1 Therapeutics, Inc. |
Morphic forms of git38 and methods of manufacture thereof
|
|
US11999802B2
(en)
|
2017-10-18 |
2024-06-04 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EA038160B1
(ru)
*
|
2017-11-30 |
2021-07-15 |
Астразенека Аб |
Модуляторы рецептора эстрогена
|
|
CN109867659A
(zh)
*
|
2017-12-04 |
2019-06-11 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物的制备方法
|
|
US10519152B2
(en)
*
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
CN112041294B
(zh)
*
|
2018-02-23 |
2024-02-20 |
晶体工程智能研究中心 |
泛醇的共晶和包含所述共晶的组合物
|
|
EA202092171A1
(ru)
|
2018-03-14 |
2020-12-01 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Схема дозирования модулятора сборки капсида
|
|
CN112566666A
(zh)
|
2018-05-14 |
2021-03-26 |
努瓦申生物公司 |
靶向抗癌核激素受体的化合物
|
|
WO2019228443A1
(en)
*
|
2018-05-30 |
2019-12-05 |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
Selective estrogen receptor downregulators and uses thereof
|
|
IL278063B2
(en)
|
2018-06-21 |
2025-08-01 |
Hoffmann La Roche |
Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
|
|
JOP20200344A1
(ar)
|
2018-07-03 |
2020-12-31 |
Univ Illinois |
منشطات لاستجابة البروتين غير المطوي
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
WO2020132785A1
(en)
*
|
2018-12-24 |
2020-07-02 |
Inventisbio Shanghai Ltd. |
Novel salts of selective estrogen receptor degraders
|
|
MA55020A
(fr)
|
2019-02-22 |
2021-12-29 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
BR112021021454A2
(pt)
|
2019-05-06 |
2021-12-21 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
|
|
JP2022532342A
(ja)
|
2019-05-14 |
2022-07-14 |
ニューベイション・バイオ・インコーポレイテッド |
抗がん核内ホルモン受容体標的化化合物
|
|
JP7616794B2
(ja)
|
2019-07-07 |
2025-01-17 |
オレマ ファーマシューティカルズ インク． |
エストロゲン受容体アンタゴニストのレジメン
|
|
US11278532B2
(en)
|
2019-08-06 |
2022-03-22 |
Recurium Ip Holdings, Llc |
Estrogen receptor modulators for treating mutants
|
|
KR20220103977A
(ko)
*
|
2019-11-04 |
2022-07-25 |
리커리엄 아이피 홀딩스, 엘엘씨 |
에스트로겐 수용체 조절제의 염 및 형태
|
|
TW202131930A
(zh)
|
2019-11-13 |
2021-09-01 |
美商諾維雪碧歐公司 |
抗癌核荷爾蒙受體標靶化合物
|
|
MX2022007659A
(es)
|
2019-12-20 |
2022-07-19 |
C4 Therapeutics Inc |
Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr).
|
|
CN116731064A
(zh)
|
2020-01-10 |
2023-09-12 |
江苏恒瑞医药股份有限公司 |
三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用
|
|
MX2022010952A
(es)
|
2020-03-05 |
2022-10-07 |
C4 Therapeutics Inc |
Compuestos para la degradacion dirigida de brd9.
|
|
EP4114391B1
(en)
|
2020-03-06 |
2025-07-09 |
Olema Pharmaceuticals, Inc. |
Compositions for use in a method of treating an estrogen receptor associated cancer
|
|
JP7719796B2
(ja)
|
2020-04-24 |
2025-08-06 |
アストラゼネカ・アクチエボラーグ |
医薬製剤
|
|
IL297216A
(en)
|
2020-04-24 |
2022-12-01 |
Astrazeneca Ab |
Dosage regimen for the treatment of cancer
|
|
WO2021253380A1
(en)
*
|
2020-06-19 |
2021-12-23 |
InventisBio Co., Ltd. |
Oral formulations and uses thereof
|
|
JP2023538517A
(ja)
|
2020-08-05 |
2023-09-08 |
シーフォー セラピューティクス， インコーポレイテッド |
Ｒｅｔの標的分解のための化合物
|
|
US20230263734A1
(en)
*
|
2020-08-05 |
2023-08-24 |
Aizant Drug Research Solutions Private Limited |
Solid dosage forms of palbociclib
|
|
WO2022109395A2
(en)
|
2020-11-23 |
2022-05-27 |
Sanofi |
Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
|
|
JP2024502270A
(ja)
*
|
2020-12-23 |
2024-01-18 |
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー |
エストロゲン受容体調節薬
|
|
TW202304928A
(zh)
|
2021-03-23 |
2023-02-01 |
美商諾維雪碧歐公司 |
抗癌核荷爾蒙受體標靶化合物
|
|
US12006314B2
(en)
|
2021-05-03 |
2024-06-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN117940133A
(zh)
|
2021-06-08 |
2024-04-26 |
C4医药公司 |
用于突变braf的降解的治疗剂
|
|
AU2022305957A1
(en)
*
|
2021-07-08 |
2024-01-25 |
Olema Pharmaceuticals, Inc. |
Methods of treating estrogen receptor-associated diseases
|
|
US20240374581A1
(en)
|
2021-07-09 |
2024-11-14 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Salt types of tricyclic tetrahydro isoquinoline derivative
|
|
WO2023221123A1
(en)
*
|
2022-05-20 |
2023-11-23 |
Olema Pharmaceuticals, Inc. |
Crystalline forms of an estrogen receptor antagonist
|
|
EP4565585A1
(en)
|
2022-08-03 |
2025-06-11 |
Bristol-Myers Squibb Company |
Compounds for modulating ret protein
|
|
JP2025540907A
(ja)
|
2022-11-04 |
2025-12-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｒｅｔ－ｌｄｄタンパク質分解誘導剤
|
|
CN120530116A
(zh)
|
2022-11-04 |
2025-08-22 |
百时美施贵宝公司 |
Ret-ldd蛋白抑制剂
|
|
KR20240170460A
(ko)
*
|
2023-05-25 |
2024-12-03 |
주식회사 삼양홀딩스 |
팔보시클립의 경구용 조성물
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
WO2025189056A1
(en)
|
2024-03-08 |
2025-09-12 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and their use in treating disease
|